HBM Healthcare Investments

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Amicus is dedicated to service of research-based pharmaceutical and healthcare companies who choose to enter the Balkans and the Baltics in partnership, and not entirely with their own subsidiaries. The company is staffed by a unique group of skilled managers and medical professionals who are dedicated to bring modern medicines to the people of our two regions. We are a service-oriented, high quality and ethically-driven company.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, focused on developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012, ObsEva aims to address significant medical needs in this area, particularly through its lead product, Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist intended to treat pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The company is also advancing OBE022, a selective oral prostaglandin F2α receptor antagonist for treating preterm labor in women between 24 to 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist designed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The founding team comprises experienced professionals in reproductive medicine and biopharmaceuticals, bringing a wealth of expertise to the company's mission.

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

BRONCUS MEDICAL INC. specializes in diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company develops a range of products including the Archimedes System, which serves as a lung access platform featuring bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning, navigation, and tunneling. Additionally, it offers the Archimedes Planner and Lungpoint systems, which provide pre-procedure planning and real-time navigation during lung biopsies. BRONCUS is also focused on treating emphysema through its Exhale product line, which employs a patented method called Airway Bypass, potentially the first minimally-invasive procedure for treating homogeneous emphysema. The company is currently enrolling patients in the pivotal EASE Trial to further investigate this treatment. Founded in 1997 and originally known as Broncus Technologies, BRONCUS is headquartered in San Jose, California, with an office in Shanghai, China, and another location in Mountain View, California.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

BRONCUS MEDICAL INC. specializes in diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company develops a range of products including the Archimedes System, which serves as a lung access platform featuring bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning, navigation, and tunneling. Additionally, it offers the Archimedes Planner and Lungpoint systems, which provide pre-procedure planning and real-time navigation during lung biopsies. BRONCUS is also focused on treating emphysema through its Exhale product line, which employs a patented method called Airway Bypass, potentially the first minimally-invasive procedure for treating homogeneous emphysema. The company is currently enrolling patients in the pivotal EASE Trial to further investigate this treatment. Founded in 1997 and originally known as Broncus Technologies, BRONCUS is headquartered in San Jose, California, with an office in Shanghai, China, and another location in Mountain View, California.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

BRONCUS MEDICAL INC. specializes in diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company develops a range of products including the Archimedes System, which serves as a lung access platform featuring bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning, navigation, and tunneling. Additionally, it offers the Archimedes Planner and Lungpoint systems, which provide pre-procedure planning and real-time navigation during lung biopsies. BRONCUS is also focused on treating emphysema through its Exhale product line, which employs a patented method called Airway Bypass, potentially the first minimally-invasive procedure for treating homogeneous emphysema. The company is currently enrolling patients in the pivotal EASE Trial to further investigate this treatment. Founded in 1997 and originally known as Broncus Technologies, BRONCUS is headquartered in San Jose, California, with an office in Shanghai, China, and another location in Mountain View, California.

Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants branded as SPI (Swiss Precision Implant). The company focuses on creating innovative and precisely designed implant systems that enhance patient comfort during surgical procedures and ensure long-term stability of the implants. Thommen Medical also offers biomaterial solutions for bone and tissue regeneration, collaborating with leading scientific and dental clinicians to improve the effectiveness and usability of its products. Through its commitment to design excellence and innovation, Thommen Medical aims to achieve optimal success for its clients in the field of dental implants.